



Contents lists available at [ScienceDirect](#)

Journal of Immunological Methods

journal homepage: [www.elsevier.com/locate/jim](http://www.elsevier.com/locate/jim)



## Corrigendum

# Corrigendum to “Optimized protocols for studying the NLRP3 inflammasome and assessment of potential targets of CP-453,773 in undifferentiated THP1 cells” [Journal of Immunological Methods 467 (2019) 19-28]



Julia A. Guzova<sup>a,c</sup>, Michael J. Primiano<sup>a</sup>, Aiping Jiao<sup>a</sup>, Jeffrey Stock<sup>b</sup>, Chiachin Lee<sup>b</sup>, Aaron R. Winkler<sup>a</sup>, J. Perry Hall<sup>a,\*</sup>

<sup>a</sup> Inflammation & Immunology Research Unit, Pfizer, Cambridge, MA 02139, United States

<sup>b</sup> Department of Discovery Sciences, Pfizer, Groton, CT 06340, United States

<sup>c</sup> Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, United States

The authors regret that in the title, in the abstract, and throughout much of the text of the manuscript the compound name CP-456,773

was inadvertently changed to CP-453,773. The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.jim.2019.02.002>

\* Corresponding author.

E-mail address: [james.p.hall@pfizer.com](mailto:james.p.hall@pfizer.com) (J.P. Hall).

<https://doi.org/10.1016/j.jim.2019.03.012>